Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1127262

registered interest
date	16/05/2019
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Pneumococcal Diseases: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what financial commitment they intend to make to the Advanced Market Commitment pilot for pneumococcal vaccine beyond 2020; and what estimate they have made of the expected total funding.
tabling member printed	Lord Stevenson of Balmacara
uin	HL15815
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines is a dynamic financing instrument of Gavi, the Vaccine Alliance. Its objective is to reduce deaths from severe pneumonia by reducing the cost of the pneumococcal vaccine. The AMC does this by incentivising vaccine manufacturers and generating greater competition by encouraging additional manufacturers to the market. So far, 114 million children have been vaccinated with AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>The expected total funding for DFID’s contribution to AMC is $485 million from 2010 until the programme completes in 2020. To date, the UK have made no new financial commitments for AMC beyond completion of the programme in 2020. As part of the planning process for the next phase for Gavi, the UK and other stakeholders are exploring all innovative financing options which can improve global immunisation in poor countries.</p> answering member printed Baroness Sugg question first answered 30/05/2019 12:54:48 answering member 4584 label Biography information for Baroness Sugg
tabling member	4175 label Biography information for Lord Stevenson of Balmacara

1127263

registered interest
date	16/05/2019
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Pneumococcal Diseases: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the effectiveness of the Advanced Market Commitment for pneumococcal vaccines; and whether it should be continued.
tabling member printed	Lord Stevenson of Balmacara
uin	HL15816
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines (PCV) incentivises vaccine manufacturers and generates competition by encouraging additional manufacturers to the market. So far, 114 million children have been vaccinated with AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>The UK assess AMC to be an effective and efficient mechanism to improve vaccine coverage at a lower cost. It scored an A+ in its last annual review. In March 2019, Pfizer reduced the price of PCV for 73 developing countries from US$3.30 in 2017 to US$2.90 per dose. This further reduction is estimated to save Gavi and developing country governments up to US$ 4.1 million.</p><p> </p><p>An independent 2015 evaluation identified AMC’s supply arrangements as a critical factor in encouraging vaccine manufacturers to expand their capacity to produce safe, effective vaccines. As part of the planning process for the next phase for Gavi, the UK and other stakeholders are exploring all innovative financing options which can improve global immunisation in poor countries.</p> answering member printed Baroness Sugg question first answered 30/05/2019 12:55:11 answering member 4584 label Biography information for Baroness Sugg
tabling member	4175 label Biography information for Lord Stevenson of Balmacara

1127264

registered interest
date	16/05/2019
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	International Finance Facility for Immunisation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will commit to supporting the International Finance Facility for Immunisation in the next funding period.
tabling member printed	Lord Stevenson of Balmacara
uin	HL15817
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The International Financing Facility for Immunisation (IFFIm) was launched in 2006. IFFIm’s frontloading capability for vaccine funding has allowed more than 80 million children to be immunised ahead of time, without having to wait until Gavi has received pledged donor grants.</p><p> </p><p>Subject to continued strong performance, the UK will fund IFFIm until 2029. More broadly, the UK recognises the important role of innovative financing mechanisms for vaccine delivery. In our role as hosts of the 2020 Gavi Replenishment, we will encourage discussions with other donors and other stakeholders on ways to expand innovative financing to vaccinate children in poor countries.</p> answering member printed Baroness Sugg question first answered 30/05/2019 13:03:56 answering member 4584 label Biography information for Baroness Sugg
tabling member	4175 label Biography information for Lord Stevenson of Balmacara